Company Description
Cuprina Holdings is a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors.
Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards.
We manufacture and distribute a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name.
The MEDIFLY products are used as a biological debridement tool for chronic wounds. In addition to our currently commercialized MEDIFLY products, we have two lines of chronic wound care products in our pipeline.
| Country | Singapore |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | David Quek Yong Qi |
Contact Details
Address: c/o Blk 1090 Lower Delta Road #06-08, 169201 Singapore | |
| Phone | +65 8512 7275 |
| Website | cuprina.com.sg |
Stock Details
| Ticker Symbol | CUPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | SGD |
| CIK Code | 0001995704 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Quek Yong Qi | Director and Chief Executive Officer |
| Baptista Carl Marc | Director and Chief Technology Officer |
| Teo Peng Kwang | Director |
| Jimmy Lee Peng Siew | Director |
| Koh Pee Keat | Independent Director |
| Ivan Ng | Independent Director |
| Natasha Kaur Raina | Independent Director |
| Chan Tat Jing | Financial Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | EFFECT | Notice of Effectiveness |
| Feb 14, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Feb 5, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jan 7, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Dec 17, 2024 | RW | Filing |
| Dec 6, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Dec 6, 2024 | RW | Filing |
| Sep 30, 2024 | EFFECT | Notice of Effectiveness |
| Sep 26, 2024 | 8-A12B | Registration of securities |
| Sep 23, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |